This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Peijia Medical Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yi Zhang

Algemeen directeur

CN¥1.5m

Totale compensatie

Percentage CEO-salaris	50.7%
Dienstverband CEO	12.3yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yi Zhang's beloning veranderd ten opzichte van Peijia Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥252m
Mar 31 2024	n/a	n/a	-CN¥322m
Dec 31 2023	CN¥1m	CN¥740k	-CN¥393m
Sep 30 2023	n/a	n/a	-CN¥460m
Jun 30 2023	n/a	n/a	-CN¥528m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥1m	CN¥1m	-CN¥408m
Sep 30 2022	n/a	n/a	-CN¥449m
Jun 30 2022	n/a	n/a	-CN¥491m
Mar 31 2022	n/a	n/a	-CN¥533m
Dec 31 2021	CN¥2m	CN¥1m	-CN¥574m

Compensatie versus markt: De totale vergoeding ($USD 205.09K ) Yi } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 348.05K ).

Compensatie versus inkomsten: De vergoeding van Yi is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yi Zhang (56 yo)

12.3yrs

Tenure

CN¥1,460,000

Compensatie

Dr. Yi Zhang has been an Executive Director of Peijia Medical Limited since May 30, 2012. He serves as the Chairman and Chief Executive Officer at Peijia Medical Limited and served as its Chief Technology...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yi Zhang	Chairman & CEO	no data	CN¥1.46m	0.77% HK$ 14.8m
Leo Tsai	Chief Financial Officer	5.4yrs	geen gegevens	geen gegevens
Kongrong Pan	Chief Operating Officer	7.1yrs	geen gegevens	geen gegevens
Fong Tan Jian	Chief Technology Officer	3.7yrs	geen gegevens	geen gegevens
Ping Ye Zhang	Executive Director	4.7yrs	CN¥182.00k	0.15% HK$ 2.9m
Hong Ye	Executive Director & Company Secretary	11.9yrs	CN¥1.36m	2.02% HK$ 38.5m
Xiaoxiao Zhuang	Vice President of Sales	4.4yrs	geen gegevens	geen gegevens
Hongpeng Wang	Vice President of Marketing	5.2yrs	geen gegevens	geen gegevens
Hing Ling Chau	Company Secretary	2.3yrs	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 9996 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yi Zhang	Chairman & CEO	12.3yrs	CN¥1.46m	0.77% HK$ 14.8m
Ping Ye Zhang	Executive Director	6.1yrs	CN¥182.00k	0.15% HK$ 2.9m
Hong Ye	Executive Director & Company Secretary	11.9yrs	CN¥1.36m	2.02% HK$ 38.5m
Stephen Newman Oesterle	Independent Non-Executive Director	4.7yrs	CN¥1.55m	geen gegevens
Huacheng Wei	Independent Non-Executive Director	3yrs	CN¥315.00k	geen gegevens
Wai Ming Yip	Independent Non-Executive Director	4.7yrs	CN¥314.00k	geen gegevens
Fei Chen	Non-Executive Director	5.3yrs	geen gegevens	geen gegevens
Robert Parks	Independent Non-Executive Director	4.7yrs	CN¥1.55m	geen gegevens
Zhiyun Yu	Non-Executive Director	8.5yrs	geen gegevens	geen gegevens
Jifeng Guan	Non-Executive Director	4.9yrs	geen gegevens	geen gegevens
Jun Yang	Non-Executive Director	4.1yrs	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9996 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

This company listing is no longer active

Peijia Medical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Recent updates

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Less than half of directors are independent

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast to breakeven in 2025

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd